Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting injections, complex active pharmaceutical ingredients (APIs) and formulations. The company’s lead product is Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly IM injection of 40mg GA for the treatment of multiple sclerosis (a $20 billion market).
Ehud Marom
About Mapi
MAPI has significant knowhow and expertise in the field of long acting injectables and extended release formulations.
The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company’s pipeline, for the treatment of MS. The product is a LCM version of Copaxone®, which requires injections daily or every other day. Mapi Pharma partnered with Mylan N.V. (NASDAQ: MYL) for GA Depot in an agreement under which Mylan was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
Mapi is engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate, Buspirone ER for the treatment of schizophrenia, GLP-1 depots for the treatment of Diabetes and other long acting Depot injectable treatments.
Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs.
Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.
Mapi's facilities
Mapi is headquartered in Israel, with R&D facilities in Israel and China, an API production facility in the Neot-Hovav Eco Industrial Park and an aseptic manufacturing and a Fill & Finish facility for injectable Finished Dosage Forms in Jerusalem.
Our Focus
- Development of long-acting depot drugs: such as Glatiramer Acetate for RRMS and PPMS, Paliperidone and Aripiprazole or Schizophrenia, GLP-1 for Diabetes.
- Sterile injectable drugs: such as GA Depot, gCopaxone
- Development of long-acting oral solid forms: such as Pregabalin ER
- GMP Manufacturing of API
- GMP Manufacturing of Finished Dosage Forms (FDF): such as Fingolimod
- Loaded Exosomes for treating: such as Parkinson’s disease, Alzheimer's, MS, ALS, GBM
- Combination treatments of stem-cells and cell derivatives such as exosomes with pharmaceuticals
Areas of Interest
- Investment: Mapi Pharma raised to-date: $135 million (including $20 million up-front) and is looking for additional capital to advance clinical programs such as Pregabalin ER for the EU market and other long-acting depot injectable programs and exosomes based treatments
- Collaboration: Mapi is open for collaboration in its fields of its expertise with pharmaceutical companies
- GMP Manufacturing: Mapi is open for specialty API, FDF and sterile injectable
- COVID-19: Approved vaccination F&F manufacturing
About Stem-Cell Medicine
Stem-Cell Medicine (SCM), sister-company of Mapi-Pharma, is a biotechnology Company that develops 2nd generation (exosomes) cell therapy products as stand-alone treatments or as combinations with pharmaceuticals. SCM is focusing on neurological indications, including Autism, MS, Pain, ALS and neuromuscular injuries.